The European Medicines Agency (EMA) yesterday authorized a booster dose in the general adult population with Moderna’s covid-19 vaccine between six and eight months after the second injection.
The European regulator revised the data presented by the American Pharmacist showing that a third dose of this preparation, between six and eight months after the second, “caused an increase in antibody levels” in adults in which they had decreased over time.
The booster dose of Moderna caused an increase in antibody levels in adults in which they decreased over time.
O secundary effects with the booster dose are similar to those caused by the second, while “the risk of inflammatory heart disease” and other adverse effects “are carefully controlled,” says the EMA.
The community agency publishes this opinion so that public health agencies can issue official recommendations on the use of a booster dose with Moderna, which will take into account several factors, such as the local epidemiological situation.
booster dose
This is the second time this month that the EMA has endorsed the safety and effectiveness of a booster dose with mRNA vaccines, since in early October it gave its approval for a third dose with Pfizer at least six months after the second in adults over 18 years of age.
In early October, the EMA already approved the additional dose with Pfizer in adults over 18 years of age
The booster dose in the general population is different from the additional dose for people with immunity system very weakened.
In this second case, the EMA already recommended the administration of an additional dose of both to do as of Modern at least 28 days after the second injection. Decisions on the vaccination campaign in the European Union (EU) are the prerogatives of each country.
.